A cure for prostate cancer is one step closer thanks to a dedicated Newcastle researcher and the local community . . .
Mater Hospital researcher Professor Jim Denham is determined to find a cure for prostate cancer.
And so are Mark and Geneane Gusse.
So determined in fact, the Hamilton couple donated $15,000 worth of jewellery to the Hunter Medical Research Institute’s raffle.
The raffle, supported by the Hunter community, raised $30,000 for the professor’s latest research project and helped get it off the ground.
A family history of prostate cancer is the main reason the couple, who own Gallerie Fine Jewel-lery at Kotara, donated the pieces.
Mr Gusse lost his father, grandfather and uncle to the disease.
“The family history was like the indicator for me. I have a yearly Prostate Specific Antigen test but my focus isn’t just on me, it’s for my son and his son and for the future.”
Mr Gusse said he would also like to see more of a focus and education on prostate cancer.
“Men are afraid to talk about it. I would like to see prominent men, who have had prostate cancer, talk about it and raise the awareness.”
But what Mr Gusse wants the most is for Prof Denham to ring him and tell him he’s solved it.
The money raised by the Gusses’ donation has gone towards the RADAR trial.
It is an extension to Prof Denham’s previous research 96.01 trial conducted with the Trans-Tasman Radiation Oncology Group, which found three months of hormone therapy treatment before radiotherapy treatment reduced the chances of cancer returning in the prostate by about 45 per cent.
Prof Denham said the 96.01 trial had accelerated the progress towards a prostate cancer cure but he wanted to do more.
He said when the trial was finished, there would be more to be done.
“We’re always trying to better the last kind of treatment results.”
The Tingira Heights professor said he had used some of his own money to develop the new trial.
“Before Mark and Geneane, I had $160,000 of personal debt and I didn’t have that much money in my pocket.
“The money came at a fantastic time. I am very grateful for Mark and Geneane’s generous contribution.”
The current trial is estimated to cost $11 million by the time it ends in 2012.
The majority of this funding will come from the National Health and Medical Research Council.
The RADAR and 96.01 trials
The RADAR trial will investigate whether radiation treatment and 18 months of hor-mone therapy, with or without the bone cancer drug Zoledronate, will produce even better results than the 96.01 trial.
Prof Denham’s latest findings from the 96.01 trial identified new measures of patient progress using Prostate Specific Antigen blood tests that could halve the time of future clinical trials in prostrate cancer.
There are 1071 men from both sides of the Tasman enrolled in the RADAR trial with major results expected to be reported in 2012.